Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment.

ABSTRACT:

Background

HER2-low cancers are heterogeneous with different degrees of HER2 expression and hormone receptor (HR) status. Currently, its analysis is mostly focused on the standard clinic-pathologic features or common biomarkers expression, without considering the heterogeneity within the category. A further characterization and understanding of this cancer subgroup will facilitate its management.

Methods

A large cohort of HER2-negative cancers (N = 1464) was included. The HER2-low (N = 412) and HER2-zero cancers (N = 1052) were compared and correlated with a comprehensive panel of clinico-pathologic features and biomarker expression according to different HER2 expressions and HR statuses. The prognostic values of these features in HER2-low cancers were also evaluated.

Fin

SUBMITTER: Li Y 

PROVIDER: S-EPMC10130469 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature